

ABL Enters into an International Distribution and Licence Agreement for the virco®TYPE HIV Resistance Interpretation System Through ABL's TherapyEdge-ViroScore™ Platform

LUXEMBOURG--(BUSINESS WIRE)--Advanced Biological Laboratories (ABL) is pleased to announce its recent signature of a non-exclusive international distribution agreement (excluding United States, Australia, Canada and United Kingdom) of virco®TYPE HIV-1, Belgium-based Virco BVBA's HIV resistance interpretation system.

ABL will offer virco®TYPE HIV-1 through its electronic medical record and decision support system TherapyEdge™ HIV. virco®TYPE HIV-1 results (raw data and report) will be available together with full patient's details and will support the healthcare providers' virological and clinical decisions taking care of HIV-infected patients experiencing virological failure and HIV drug resistance.

The distribution of virco®TYPE HIV-1 will complete ABL's portfolio of online services in electronically based bioinformatics tools currently provided through its TherapyEdge™ and ViroScore™ Suite platform.

ABL distributes several proprietary systems developed by international experts companies and research teams, including the COMET® software (virus subtype characterization, licensed from the CRP-Santé (www.crp-sante.lu), in Luxembourg, the FibroMeter™ viral Hepatitis online interpretation system (liver fibrosis scoring from BioLiveScale (www.biollivescale.com), in France) and the SeqHepB® online interpretation system (HBV drug resistance interpretation system from Evivar Medical (www.evivar.com), in Australia).

The ViroScore™ Suite platform includes also several genotypic HIV drug resistance interpretation algorithms developed and validated by several worldwide HIV/AIDS experts from medical hospitals and universities in the USA, in Belgium, in France, in Spain, in Luxembourg and in Brazil.

About ABL: Advanced Biological Laboratories (ABL) S.A. is an information technology company dedicated to develop healthcare products and services to enable its customers deliver high-quality and optimal personalized healthcare by streamlining processes and improving the quality and safety of patient care. Over the last 10 years, ABL has developed its proprietary TherapyEdge Electronic Medical Record System, to manage all conditions, medications, and laboratory tests, with integrated modules to enable personalized disease management using clinical, biological and genetics decision support algorithms for HIV/AIDS, Viral Hepatitis and Tuberculosis. The TherapyEdge and ViroScore Suite platforms are fully integrated with hospital information systems (HIS) and laboratory information system (LIS) according industry standards. ABL is engaged in several research projects and international collaborations in the field of molecular diagnostics and personalized healthcare in the European Union, the USA, Africa and Asia. TherapyEdge™ and ViroScore™ Suite are covered by international intellectual property portfolio.

More information available at: <http://www.therapyedge.com> and <http://www.vicolab.com/hiv-resistance-products/vircotype-hiv-1>

Contacts

Advanced Biological Laboratories (ABL), S.A.

Tel: +352-2638-8921